Hot Features
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), whic... Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 4.99 | 5.085 | 4.67 | 220399 | 4.83839036 | CS |
| 4 | 0.64 | 14.7126436782 | 4.35 | 5.3 | 3.16 | 744880 | 4.34751453 | CS |
| 12 | -1.13 | -18.4640522876 | 6.12 | 6.72 | 3.16 | 572807 | 4.73714547 | CS |
| 26 | 0.95 | 23.5148514851 | 4.04 | 11.89 | 3.16 | 505482 | 5.83385636 | CS |
| 52 | 0.84 | 20.2409638554 | 4.15 | 11.89 | 3.16 | 328096 | 5.40668098 | CS |
| 156 | 4.04 | 425.263157895 | 0.95 | 20.83 | 0.2145 | 709951 | 7.07987675 | CS |
| 260 | -0.01 | -0.2 | 5 | 20.83 | 0.2145 | 555771 | 6.24812543 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.